Skip to main content

 

The RheumNow Week in Review – 2 December 2016

Dr. Cush highlights reports from this week on RheumNow.com.

Diffuse Cutaneous Systemic Sclerosis: Results of the SCOT Trial

Diffuse cutaneous systemic sclerosis (dcSSc) is one of the most difficult autoimmune diseases to treat. In case of major organ involvement (lung, kidney), prognosis is poor and treatment options are limited.

Ustekinumab Effective and Safe in Crohn's Colitis

The New England Journal of Medicine has reported the results of a large clinical trial demonstrating the efficacy of ustekinumab (Stelara) in treating patients with active Crohn's disease (CD). (Citation source http://buff.ly/2gsSNcs)

Maintenance of Remission in ANCA-vasculitis: MAINRITSAN study.

It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.

Diffuse Cutaneous Systemic Sclerosis: Results of the SCOT Trial

Diffuse cutaneous systemic sclerosis (dcSSc) is one of the most difficult autoimmune diseases to treat. In case of major organ involvement (lung, kidney), prognosis is poor and treatment options are limited.

Maintenance of Remission in ANCA-vasculitis: MAINRITSAN study.

It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.

Lilly Features it's Rheumatoid and Psoriasis Biologics at ACR 2016

Eli Lilly & Co. has multiple presentations planned for the upcoming Annual meeting of the ACR/ARHP in Washington starting on Sunday, November 13th.

Janssen's Portfolio of New Biologics Roll Out for ACR 2016

Janssen has announced the listings for it's presentations at the upcoming annual ACR/ARHP 2016 meeting in Washington.

RheumNow Week in Review – 4 November 2016

Dr. Jack Cush reviews highlights and reports from this week on RheumNow.com, including drug-induced cutaneous lupus, pediatric lupus being worse, new gout drug SEL-12, Gut microbiome and IgA plasmablasts, and the weakly-received new ACP guidelines on gout.

IgA ACPA and Plasmablasts Point to Microbiome in Pre-Clinical Rheumatoid

Serum antibodies precede the development of clinical rheumatoid arthritis (RAby) by many years, and yet we still have much to learn about this preclinical phase.

Review of Herpes Zoster with Immunosuppression and Autoimmune Disease

Researchers from the University of British Columbia reported on their systematic review and meta-analysis of risk of herpes zoster (HZ) in patients receiving biologics, DMARDs and/or corticosteroids for autoimmune diseases.

×